Arcutis Biotherapeutics
ARQT
ARQT
139 hedge funds and large institutions have $1.06B invested in Arcutis Biotherapeutics in 2022 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 68 increasing their positions, 19 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
15% more capital invested
Capital invested by funds: $914M → $1.06B (+$142M)
3.17% more ownership
Funds ownership: 95.44% → 98.61% (+3.2%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Holders
139
Holding in Top 10
5
Calls
$5.86M
Puts
$349K
Top Buyers
| 1 | +$34.4M | |
| 2 | +$24.1M | |
| 3 | +$23.2M | |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$19.1M |
| 5 |
Jennison Associates
New York
|
+$18.2M |
Top Sellers
| 1 | -$13.3M | |
| 2 | -$9.18M | |
| 3 | -$5.23M | |
| 4 |
Invesco
Atlanta,
Georgia
|
-$3.64M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.14M |